Mumbai: The global pharmaceutical market, valued at $1,559.53 billion in 2023, is projected to reach $2,832.66 billion by 2033, growing at a CAGR of 6.15% from 2024 to 2033. This growth is driven by advancements in biotechnology, personalised medicine, digital health, and global market expansion. The Indian pharmaceutical market is also based on strong R&D capabilities and strategic focus. ASEAN And encouraged India to export products to European and American markets.

leading this campaign R.V. GroupRV Group is a multinational pharmaceutical company with a significant presence in the ASEAN and CIS regions. With over 3,500 employees in nine countries, RV Group is dedicated to improving the lives of patients with high-quality, affordable curative and preventive products. Since its establishment in 2006, RV Group has become a major player in the ASEAN pharmaceutical sector.

Rajeev Sharma, chairman and founder of RV Group, explains the journey: “We started with Vietnam as our base and now we are a strong player in ASEAN. We are present in India, CIS, Europe and have a unit in Canada. Next year, we plan to launch in the US market, which will mark our global presence.”

Strengthening its presence in India Celine And Septran

India has always been a key market for the RV Group chairman, who envisions building a strong business that contributes to both the company’s growth and the availability of life-saving medicines. The recent merger with KCH and the acquisition of legacy brands like Celine and Septran is a strategic move to establish a significant presence in India. “In 2017-18, we acquired a local manufacturing unit in Aurangabad, which is European-approved. However, to make a significant impact, we needed a strong front end. This merger with KCH, which has over 450 employees on the ground and renowned brands like Celine and Septran, provides the perfect combination to make a significant impact in India,” Sharma explained.

Expansion into the ASEAN market

RV Group has consolidated its position as the strongest player in the ASEAN market with its strong presence in Vietnam, Philippines, Thailand, Cambodia and Myanmar. Sharma elaborates, “Our ground operations in ASEAN are very strong. Our Indian unit has built a product portfolio that we are looking to export to the European and US markets.”

The Power of Legacy Brands: Celine and Septran

The integration of KCH’s legacy brands Selin and Septran into Aarvee Group’s portfolio is significant. Ravindra Shenoy, Founder and Director, Koye, says, “Aarvee’s expansion into India with recognised brands like Selin and Septran provides an ideal platform to enter a market that is one of the largest in the world by demographics and volume. India is transforming from a disease-centric to a health-centric market, and these recognised brands are critical to success.”

Growth potential nutraceuticals

A growing trend in nutraceutical consumption is evident in both ASEAN and Indian markets, driven by an ageing population seeking solutions for healthy ageing. “We plan to introduce nutraceutical products in India by leveraging our strong OTC presence in countries like Vietnam, Myanmar and the Philippines. We will focus on OTC marketing in India, starting with states like Bihar and West Bengal and then expanding across the country,” says Sharma.

conclusion

The strategic merger between Aarvee Group and KCH, as well as the integration of legacy brands such as Celin and Septran, has strengthened Aarvee’s position in India. By combining manufacturing prowess with marketing expertise, Aarvee Group not only meets the growing healthcare demands of Indian consumers, but also has a significant impact on the global pharmaceutical landscape. As Aarvee Group expands into new markets, including the US and Europe, it remains committed to affordable, innovative solutions that address unmet medical needs, improving the quality of life for millions of people around the world.

(Disclaimer: The views expressed are solely of the author and ETHealthworld.com does not necessarily agree with it. ETHealthworld.com will not be responsible for any damage caused directly or indirectly to any person/organisation).